[405] developed ZL216, a novel PROTAC using nucleic acid aptamer AS1411 as a targeting ligand for nucleolin, which showed excellent serum stability and water solubility while achieving potent nucleolin degradation in breast cancer cells both in vitro and in vivo. The gene discussed is NUCLEOLIN; the disease is breast carcinoma.